Innovative Drug Development Demands Clearer Regulatory Pathways From FDA
Executive Summary
Speeding development of innovative therapies requires FDA to more clearly define regulatory pathways for novel drugs, former Abbott Pharma President & COO Jeffrey Leiden said
You may also be interested in...
FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
Quantitative measures to evaluate drug risks and benefits would provide FDA a stronger defense against critiques of regulatory decisions, several agency observers suggested
Can FDA Learn From Industry’s Risk/Benefit Decisions?
FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses
FDA Disease Models Will Focus On Areas With Poor R&D Track Records
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said